Physician profile
Faye Knoll
NPI 1669633418
$6,009.46
in general payments reported to CMS, 2019-2025
21 companies · $886 in 2025
The $886 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $411 · 2021: $509 · 2022: $1,275 · 2023: $1,178 · 2024: $1,035 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,081 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,081.34 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,578.28 | 2020-2025 | Clareon, Eysuvis, Argos |
| Oyster Point Pharma, INC. | $532.62 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $445.87 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $439.26 | 2022-2024 | Miebo, Envista Mx60 Iol |
| Biotissue Holdings INC. | $360.76 | 2019-2024 | |
| Ocular Therapeutix, INC. | $277.04 | 2022-2025 | Dextenza |
| Kala Pharmaceuticals, INC. | $263.76 | 2019-2021 | |
| Glaukos Corporation | $249.39 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $242.78 | 2019-2023 | |
| Dompe US, INC. | $240.18 | 2019-2024 | Oxervate |
| Shire North American Group INC | $228.03 | 2019 | |
| Sun Pharmaceutical Industries INC. | $225.27 | 2019-2025 | Cequa |
| Harrow Eye, LLC | $183.23 | 2024-2025 | Vevye |
| Abbvie INC. | $177.43 | 2023-2025 | |
| Rxsight INC | $144.01 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $125.00 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $93.27 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $82.89 | 2019-2022 | |
| Horizon Therapeutics Plc | $46.86 | 2019-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.29 | 2021 | |
| Rayner Intraocular Lenses Limited | $28.24 | 2024 | Omidria, Rayone Emv, Rayone Aspheric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faye Knoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.